MTT法抗癌药物敏感性试验指导下腹腔化疗的研究

目的 观察MTT法体外药敏试验指导下晚期肿瘤腹腔化疗的疗效.方法 提取恶性腹水中的肿瘤细胞,采用MTT比色法测定肿瘤细胞对化疗药物的敏感性,选择对肿瘤细胞抑制率最高的一种化疗药物进行腹腔化疗.结果 MTT法测定药物敏感者腹腔化疗有效率达62.5%,不敏感者均无效;在改善患者生活质量中,药敏有效组明显优于无效组;实验结果与临床有效率有中度相关性.结论 用MTT法检测药物敏感性指导腹腔化疗是一种简便、快速、有效的方法.     

直肠癌组织中CD133蛋白的表达与临床病理特征及化疗敏感性的相关性研究

目的探讨直肠癌组织中CD133蛋白的表达与临床病理特征及化疗敏感性的相关性。方法应用免疫组织化学染色方法检测临床病理确诊的360例直肠癌患者的肿瘤组织中CD133蛋白的表达情况,并提取新鲜组织中肿瘤细胞进行体外培养,利用胶滴药敏试验方法检测其对化疗药的敏感性,综合分析CD133蛋白的表达与临床病理特征及化疗敏感性的关系。结果 CD133阳性染色呈棕黄色,定位于腺腔内细胞膜,而癌旁非肿瘤性肠黏膜中无CD133阳性表达。CD133高表达与肿瘤分化程度、TNM分期及淋巴结转移有关(P0.05),而与患者的性别、年龄无相关性(P0.05)。Logistic回归分析显示肿瘤分化程度(P=0.015)、TNM分期(P=0.032)及淋巴结转移(P=0.007)是CD133蛋白表达阳性的独立危险因素。Pearson等级相关性分析显示CD133的阳性表达与化疗敏感性呈负相关(r=-0.39,P0.01),CD133表达阴性的患者对于该化疗方案的敏感性显著高于CD133表达阳性的患者(P=0.037),且随着分化程度降低、TNM分期增加及淋巴结转移的发生,化疗敏感性均显著下降(P均0.01)。结论直肠癌组织中CD133蛋白的表达与临床病理特征及化疗敏感性有着密切联系,通过检测CD133蛋白水平可为直肠癌的早期诊断与预后评估提供临床依据。     

结肠癌转移淋巴结P-gp、Bcl-2、Bax表达与体外化疗敏感性的关系

目的 探讨结肠癌淋巴结转移灶多药耐药相关因子P-gp、Bcl-2、Bax表达及其与肿瘤细胞体外化疗敏感性的关系.方法 对新鲜结肠癌肿瘤组织及转移淋巴结进行肿瘤细胞培养体外化疗药敏性试验,并对原发灶和转移灶行P-gp、Bcl-2、Bax免疫组化染色.结果 ①P-gp、Bax在转移灶中的表达程度明显高于原发灶(均P<0.05),而Bcl-2在原发灶中表达强于转移灶(P<0.01).在原发灶与转移淋巴结间P-gp、Bax表达均具有明显相关性 (r=0.660 6、0.399 5,均P<0.01).②在结肠癌原发灶中Bcl-2与Bax表达呈正相关(r=0.305 1,P<0.05).③10种化疗药物中5-FU、VP-16、THP、MMC对转移淋巴结肿瘤细胞的抑制率高于原发灶;HCPT、L-OHP、CDDP、VCR对原发灶肿瘤细胞抑制率高于转移灶(均P<0.05).④P-gp表达程度在原发灶与5-FU、VCR、PTX、VP-16的肿瘤细胞抑制率呈负相关,在转移灶则与PTX、eADM呈负相关;Bcl-2在原发灶表达强度与5-FU、PTX、MMC的抑制率呈负相关,在转移淋巴结中则与HCPT、PTX、L-OHP、eADM的抑制率均具有负相关性;Bax表达强度在原发灶与5-FU、VP-16对肿瘤细胞的平均抑制率呈正相关,在转移灶则随CDDP、L-OHP、eADM抑制率升高而增强(均P<0.05).结论 结肠癌淋巴结转移灶中耐药相关因子的表达及化疗药敏性均呈现与原发灶不同的异质性,术后辅助化疗应针对淋巴结转移灶进行.     

急性非淋巴细胞白血病化疗药物集落法体外敏感试验的临床应用评价

采用骨髓白血病祖细胞体外培养法(L-CFU培养)测定31例急性非淋巴细胞白血病(ANLL)患者体外药物敏感性,同时观察同种抗癌药物诱导化疗后的临床疗效。实验结果表明,以≥40%细胞杀伤率为体外药物敏感阈值,体内外药敏符合率83.33%,耐药符合率92.31%。此方法判断标准简捷,有助于预测ANLL患者对化疗药物的体内反应,具有一定的临床应用价值。     

进展期胃癌原发灶与转移灶体外药敏的相关性（附60例病例报告）

目的探讨胃癌原发灶（癌细胞）与转移灶（转移淋巴结癌细胞）体外化疗药物敏感性,及其两者之间的相关性。方法将手术切除的60例胃癌病人肿瘤组织、转移淋巴结标本,采用MTT法分别检测氟尿嘧啶（FU）、顺铂（CDDP）、奥沙利铂（L—OHP）、伊立替康（CPT—11）、氟尿嘧啶＋顺铂和氟尿嘧啶＋奥沙利铂6种方案对2种不同组织细胞的抑制率。结果转移淋巴结和癌组织细胞对4种单药化疗方案（FU、CDDP、L—OHP、CPT-11）之间的敏感性差异无显著意义（P〉0．05）;两种组织对4种单药化疗方案与2种组合化疗方案之间有显著差异;转移淋巴结与癌组织细胞对6种化疗方案（FU、CDDP、L—OHP、CPT-11、FU＋CDDP和FU＋L—OHP）的敏感性呈正相关。结论根据原发灶体外药敏结果指导化疗更具科学性。     

改良MTT法检测胃肠癌体外化疗药物敏感性

目的 探讨胃肠癌对常用化疗药物的敏感性。方法 应用改良MTT法进行了化疗药物的体外药敏试验。结果 不同病例对同一药物的敏感性不同，有其各自的耐药谱。结论 根据体外药敏试验实行个体化用药方案，可提高临床化疗疗效。     

乳腺癌细胞药敏试验临床应用价值探讨

目的探讨采用组织块培养、终点染色、计算机图像分析法(TECIA)在乳腺癌化疗中的临床意义及应用价值。方法选用10种常用乳腺癌化疗药物及临床常用的五组联合化疗方案,我们TECIA对75例乳腺癌改良根治术标本,评估肿瘤细胞对化疗药物的敏感性及联合化疗方案选择的合理性。结果化疗药物对乳腺癌的杀伤作用具有较强的个体差异性,10种化疗药物的敏感性分别为5-氟尿嘧啶(5-Fu)33.3%、顺铂(DDP)37.5%、环磷酰胺(CTX)29.2%、足叶已甙(VP-16)16.7%、丝裂霉素(MMC)22.0%、表阿霉素(EPI)41.7%、诺维本(NVB)45.8%、阿霉素(ADM)41.7%、泰素(PTX)54.2%、氨甲喋呤(MTX)25.0%。五组联合化疗方案的敏感性分别为CAF:环鳞酰胺(CTX)+阿霉素(ADM)+5-氟尿嘧啶(5-FU)33.2%;CMF:环鳞酰胺(CTX)+氨甲喋呤(MTX)+5-氟尿嘧啶(5-FU)26.6%;TA:泰素(PTX)+阿霉素(ADM)31.2%;NP诺维本(NVB)+顺铂(DDP)45.2%;TP:泰素(PTX)+顺铂(DDP)40.1%。结论体外肿瘤药敏试验在乳腺癌的临床用药及个体化化疗方面具有重要的指导意义,其检测结果与临床实际疗效具有良好相关性,可用于指导乳腺癌术后化疗。     

外周血淋巴细胞与食管癌细胞对化疗药物抑制率相关性检测及其临床意义

利用噻唑蓝（MTT）法检测6种化疗药物对24例食管癌患者外周血淋巴细胞的抑制率，并与体外肿瘤细胞抑制率进行对比分析。结果 二者抑制率无统计学意义（P〉0．05），但呈正相关（r=0．657．P〈0．01）。对15例食管癌手术患者根据外周血淋巴细胞药敏实验指导治疗（指导组），结果 2年生存率明显高于经验治疗组（P〈0．05）。提示外周血淋巴细胞化疗药物敏感性检测对临床选择化疗药物有一定参考价值。     

三磷酸腺苷生物荧光体外药物敏感性检测在老年非小细胞肺癌胸水中的应用

非小细胞肺癌占肺癌的80%左右,80%以上患者确诊时已达Ⅲb-Ⅳ期,即为晚期或局部晚期,已失去根治性手术切除机会,治疗上以全身化疗为主进行综合治疗.但由于老年人生理性功能退化与伴随疾病的存在,使老年患者对化疗的耐受性下降,不良反应增加.针对老年肿瘤患者在化疗前及化疗后产生耐药现象,通过对体外药敏试验为每位患者筛选敏感性药物进行个体化治疗,可望提高疗效,减少不良反应,防止多药耐药的发生.本文应用目前较先进的ATP生物荧光(ATP-TCA)技术[1],体外检测24例初治局部晚期或晚期及复发或转移老年非小细胞肺癌患者胸水标本,每例患者均按非小细胞肺癌NCCN治疗指南选择一线及二线化疗药物进行体外药敏检测.     

人非小细胞肺癌细胞的原代培养及个体化药敏实验研究

目的探讨MTr法在原代肺癌细胞药物敏感性试验研究中的应用价值及NSCLC对5种（长春瑞滨、依托泊苷、长春新碱、吉西他滨、多西他赛）临床常用化疗药物的敏感性。希望能通过本课题的研究为肺癌个体化化疗敏感药物的选择提供参考。方法30例病例均取白手术新鲜组织,采取体外原代培养,MTT药敏试验,检测5种（长春瑞滨、依托泊苷、长春新碱、吉西他滨、多西他赛）临床常用化疗药物的敏感性,选取临床最佳化疗方案。结果30例NSCLC体外原代培养均成功。肺癌细胞对5种化疗药均敏感,其顺序依次为多西他赛=吉西他滨〉长春瑞滨：依托泊苷：长春新碱。结论本课题之肺癌细胞原代培养的方法可获得药敏实验所需的肺癌细胞。MTT法在原代肺癌细胞药物敏感性试验研究中具有灵敏度高、重复性好、操作简便、经济、快速、易自动化、无放射性污染等优点,值得推广。30例非小细胞肺癌细胞对多西他赛和吉西他滨最敏感,可作为临床治疗NSCLC首选之一,该实验方法可作为NSCLC个体化治疗的选择之一。     

Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition

AIM:To investigate the expression of survivin during the early stages of hepatocellular carcinoma(HCC). METHODS:Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared.In addition,to determine the survivin expression in response to anti- cancer drugs in early stage HCC,the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions. RESULTS:Survivin proteins were expressed in 64.7% of cells in early HCC specimens.A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens(low-rate group vs high-rate group)was observed.The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs. CONCLUSION:This study suggests that survivin could be used as a therapeutic target in early HCC.     

肝细胞癌患者血清leptin和MMP-9的表达及其临床意义

目的 探究肝细胞癌患者血清瘦素(leptin)及金属基质蛋白酶-9(MMP-9)的表达情况及其临床意义.方法 采用酶联免疫吸附法(ELISA)测定80例肝细胞癌患者血清leptin及MMP-9的表达水平,并与40例健康志愿者进行比较,分析影响肝细胞癌患者血清leptin和MMP-9水平的因素.两组比较采用t检验,多组比较采用方差分析,相关性检验采用Pearson分析.结果 肝细胞癌患者血清leptin、MMP-9表达水平明显高于健康对照组,升高水平与其临床分期成正比.肝细胞癌患者血清leptin、MMP-9的水平与患者合并腹水、体质量指数、肿瘤数目和大小、血管和淋巴转移情况、肿瘤胞膜完整度和肿瘤分化程度相关,且二者呈正相关(r=0.381 7,P＜0.05).结论 leptin和MMP-9在肝细胞癌患者体内出现异常表达,二者可能共同参与了其发生发展的过程.     

Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition

AIM: To investigate the expression of survivin during the early stages of hepatocellular carcinoma (HCC). METHODS: Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared. In addition, to determine the survivin expression in response to anticancer drugs in early stage HCC, the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions. RESULTS: Survivin proteins were expressed in 64.7％ of cells in early HCC specimens. A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens (low-rate group vs high-rate group) was observed. The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs. CONCLUSION: This study suggests that survivin could be used as a therapeutic target in early HCC.     

Down-regulation of iASPP in human hepatocellular carcinoma cells inhibits cell proliferation and tumor growth

The oncoprotein inhibitory member of the ASPP family (iASPP) is a key inhibitor of the p53 tumor suppressor and is upregulated in patients with acute leukemia and breast carcinoma. To investigate the effect of iASPP inhibition on the proliferation of hepatocellular carcinoma cells, a recombinant lentivirus vector expressing a small interfering RNA (siRNA) against iASPP gene expression was constructed and used to infect human hepatocellular carcinoma cells (HepG2 and Hep3B). The results showed that iASPP mRNA and protein levels were significantly down-regulated in both cells infected with the siRNA against iASPP. siRNA-mediated down-regulation of iASPP repressed tumor cell proliferation and colony formation in vitro and induced a growth delay of the tumor in vivo, suggesting that iASPP plays an important role in the proliferation of hepatocellular carcinoma cells. iASPP may be a valuable candidate target gene in hepatocellular carcinoma therapy.     

E-选择素及其配体表达对肝癌转移的临床意义

目的 探讨E-选择索(E-selectin)及其配体在肝癌细胞与内皮细胞黏附中的作用和二者表达的临床意义;并筛选可能阻断黏附作用的药物. 方法 收集78例肝细胞癌患者的临床资料,采用免疫组织化学方法检测E-selectin、sLeX、sLeA、CD44v6的表达情况,按临床特征分组并比较各组E-selectin、sLeX、sLeA、CD44v6的阳性表达率差异.体外实验采用实时荧光定量PCR检测E-selectin和细胞间黏附分子(ICAM)-1在ED25、ECV304两种内皮细胞中的表达;黏附实验检测肝癌细胞HepG2与ED25、ECV304两种内皮细胞的黏附活性,并检测不同药物对黏附作用的影响.对临床资料数据采用χ2检验、Kaplan-Meier生存分析与Wilcoxon检验;对体外实验计量数据进行方差分析.结果 E-selectin在肝癌病灶内血管内皮细胞中的阳性表达率为70.51%,sLeX、sLeA、CDJ44v6在肝癌细胞中的阳性表达率分别为64.10%、69.23%、62.90%.sLeX、sLeA、CD44v6表达阴性患者的平均生存期显著长于阳性患者(P值均<0.05).有门静脉癌栓、术前肝外转移、卫星病灶、术后3个月内复发各组E-selectin、sLeX、sLeA的阳性表达率差异均有统计学意义(P值均<0.05);而肿瘤大小、血清AFP水平均与E-selectin、sLeX、sLeA的阳性表达率无相关性;病理分级Ⅲ～Ⅳ级组与Ⅰ～Ⅱ级组的E-selectin和CD44v6的阳性表达率差异均有统计学意义(P值均<0.05).CD44v6的表达特点是术后3个月内复发者有较高的阳性率,有卫星灶者阳性率也较高.E-selectin和ICAM-1可高表达于活化后的ED25和ECV304细胞;且能介导HepG2细胞与ED25和ECV304细胞的黏附,地塞米松,丹参酮ⅡA都具有较强的抗黏附能力,且抗黏附作用随着浓度的增加而增强.结论 E-selectin、sLeX.sLeA、CD44v6的表达与患者的预后,门静脉癌栓等临床特征密切相关,可作为临床预后和术后早期复发的评估依据.E-selectin、ICAM-1及其配体可增强肝癌细胞与内皮细胞的黏附,促进肝癌转移;地塞米松、丹参酮ⅡA可阻断其黏附作用.     

E-选择素及其配体表达对肝癌转移的临床意义

目的 探讨E-选择索(E-selectin)及其配体在肝癌细胞与内皮细胞黏附中的作用和二者表达的临床意义;并筛选可能阻断黏附作用的药物. 方法 收集78例肝细胞癌患者的临床资料,采用免疫组织化学方法检测E-selectin、sLeX、sLeA、CD44v6的表达情况,按临床特征分组并比较各组E-selectin、sLeX、sLeA、CD44v6的阳性表达率差异.体外实验采用实时荧光定量PCR检测E-selectin和细胞间黏附分子(ICAM)-1在ED25、ECV304两种内皮细胞中的表达;黏附实验检测肝癌细胞HepG2与ED25、ECV304两种内皮细胞的黏附活性,并检测不同药物对黏附作用的影响.对临床资料数据采用χ2检验、Kaplan-Meier生存分析与Wilcoxon检验;对体外实验计量数据进行方差分析.结果 E-selectin在肝癌病灶内血管内皮细胞中的阳性表达率为70.51%,sLeX、sLeA、CDJ44v6在肝癌细胞中的阳性表达率分别为64.10%、69.23%、62.90%.sLeX、sLeA、CD44v6表达阴性患者的平均生存期显著长于阳性患者(P值均<0.05).有门静脉癌栓、术前肝外转移、卫星病灶、术后3个月内复发各组E-selectin、sLeX、sLeA的阳性表达率差异均有统计学意义(P值均<0.05);而肿瘤大小、血清AFP水平均与E-selectin、sLeX、sLeA的阳性表达率无相关性;病理分级Ⅲ～Ⅳ级组与Ⅰ～Ⅱ级组的E-selectin和CD44v6的阳性表达率差异均有统计学意义(P值均<0.05).CD44v6的表达特点是术后3个月内复发者有较高的阳性率,有卫星灶者阳性率也较高.E-selectin和ICAM-1可高表达于活化后的ED25和ECV304细胞;且能介导HepG2细胞与ED25和ECV304细胞的黏附,地塞米松,丹参酮ⅡA都具有较强的抗黏附能力,且抗黏附作用随着浓度的增加而增强.结论 E-selectin、sLeX.sLeA、CD44v6的表达与患者的预后,门静脉癌栓等临床特征密切相关,可作为临床预后和术后早期复发的评估依据.E-selectin、ICAM-1及其配体可增强肝癌细胞与内皮细胞的黏附,促进肝癌转移;地塞米松、丹参酮ⅡA可阻断其黏附作用.     

E-选择素及其配体表达对肝癌转移的临床意义

目的 探讨E-选择索(E-selectin)及其配体在肝癌细胞与内皮细胞黏附中的作用和二者表达的临床意义;并筛选可能阻断黏附作用的药物. 方法 收集78例肝细胞癌患者的临床资料,采用免疫组织化学方法检测E-selectin、sLeX、sLeA、CD44v6的表达情况,按临床特征分组并比较各组E-selectin、sLeX、sLeA、CD44v6的阳性表达率差异.体外实验采用实时荧光定量PCR检测E-selectin和细胞间黏附分子(ICAM)-1在ED25、ECV304两种内皮细胞中的表达;黏附实验检测肝癌细胞HepG2与ED25、ECV304两种内皮细胞的黏附活性,并检测不同药物对黏附作用的影响.对临床资料数据采用χ2检验、Kaplan-Meier生存分析与Wilcoxon检验;对体外实验计量数据进行方差分析.结果 E-selectin在肝癌病灶内血管内皮细胞中的阳性表达率为70.51%,sLeX、sLeA、CDJ44v6在肝癌细胞中的阳性表达率分别为64.10%、69.23%、62.90%.sLeX、sLeA、CD44v6表达阴性患者的平均生存期显著长于阳性患者(P值均<0.05).有门静脉癌栓、术前肝外转移、卫星病灶、术后3个月内复发各组E-selectin、sLeX、sLeA的阳性表达率差异均有统计学意义(P值均<0.05);而肿瘤大小、血清AFP水平均与E-selectin、sLeX、sLeA的阳性表达率无相关性;病理分级Ⅲ～Ⅳ级组与Ⅰ～Ⅱ级组的E-selectin和CD44v6的阳性表达率差异均有统计学意义(P值均<0.05).CD44v6的表达特点是术后3个月内复发者有较高的阳性率,有卫星灶者阳性率也较高.E-selectin和ICAM-1可高表达于活化后的ED25和ECV304细胞;且能介导HepG2细胞与ED25和ECV304细胞的黏附,地塞米松,丹参酮ⅡA都具有较强的抗黏附能力,且抗黏附作用随着浓度的增加而增强.结论 E-selectin、sLeX.sLeA、CD44v6的表达与患者的预后,门静脉癌栓等临床特征密切相关,可作为临床预后和术后早期复发的评估依据.E-selectin、ICAM-1及其配体可增强肝癌细胞与内皮细胞的黏附,促进肝癌转移;地塞米松、丹参酮ⅡA可阻断其黏附作用.     

原发性肝癌患者CD4+CD25+调节性T细胞及转化生长因子β1检测

目的探讨检测原发性肝癌患者外周血CD4+CD25+调节性T细胞(Treg)及血清转化生长因子(TGF)-β1的临床意义。方法应用流式细胞学方法和酶联免疫吸附测定方法分别检测原发性肝癌患者32例、转移性肝癌患者25例、健康体检者30例的外周血Treg占总CD4+T细胞的比例和血清TGF-β1浓度。结果原发性肝癌、转移性肝癌患者外周血Treg占总CD4+T细胞的比例与对照组比较均明显升高,差异有统计学意义(P<0.01);原发性肝癌患者外周血Treg占总CD4+T细胞的比例较转移性肝癌患者亦明显升高,差异有统计学意义(P<0.05)。原发性肝癌、转移性肝癌患者血清TGF-β1浓度与对照组比较均明显升高,差异有统计学意义(P<0.01);原发性肝癌患者血清TGF-β1浓度较转移性肝癌患者亦明显升高,差异有统计学意义(P<0.01)。相关分析显示,原发性肝癌患者外周血Treg占总CD4+T细胞的比例与病理分期、血清TGF-β1浓度呈正相关(r=0.762、r=0.698,P<0.01),与Karnofsky功能状态(KPS)评分呈负相关(r=-0.642,P<0.01)。结论原发性肝癌患者外周血Treg比例明显升高,且与血清TGF-β1浓度、病理分期和KPS评分具有一定的相关性。检测原发性肝癌患者外周血Treg占总CD4+T细胞的比例可能有助于评估原发性肝癌患者的病情进展及判断其预后。     

Antitumor activities of human autologous cytokine—induced killer（CIK）cells against hepatocellular carcinoma cells in vitro and in vivo

AIM：To characterize the anticancer function of cytokine induced killer cells(CIK) and develop an adoptive immunotherapy for the patients with primary hepatocellular carcinoma(HCC),we evaluated the proliferation rate phenotype and the antitumor activity of human CIK cells from healthy donors and HCC patients in vitro and in vivo.METHODS:Peipheral bolld mononuclear cells(PBMC) form healthy donors and patients with primary HCC were incubated in vitro and induced into CIK cells in the presence of various cytokines such as interferon-gamma(IFN-γ),interleukin-1(IL-1),IL-2,and monoclonal antibody(mAb) against CD3.The phenotype and characterization of CIK cells were identified by folw cytometric analysis.The cytotoxicity of CIK cells was detemined by ^51Cr release assay.RESULTS:The CIK cells were shown to be a heterogeneous population with different cellular phenotypes.The percentage of CD3^+/CD56^+ positive cells,the dominant effector cells,in total CIK cells from healthy donors and HCC patients,significantly increased form 0.1-0.13% at day 0 to 19.0-20.5% at day 21 incubation,which suggested that the CD^3+ CD56^+positive cells proliferated faster than other cell populations of CIK cells in the protocol used in this study.After 28 day in vitro incubation,the CIK cells from patients with HCC and healthy donors increased by more than 300-fold and 500-fold in proliferation cell number respectively,CIK cells originated from HCC patients possessed a higher in vitro antitumor cytotoxic activity on autologous HCC cells than the autologous lymphokine-activated killer(LAK) cells and PBMC cells,In in vivo animal experiment.CIK cells had stonger effects on the inhibition of tumor growth in Balb/c nude mice bearing BEL-7402-producing tumor than LAK cells(mean inhibitory rate 84.7%VS52.8%,P&lt;0.05) or PBMC(mean inhibitory rate 84.7%VS 37.1%,P&lt;0.01).CONCLUSION:Autologous CIK cells are of highly efficient cytotoxic effcetor cells against primary hepatocellular carcinoma cells and might serve as an alternative adoptive therapeutic strategy for HCC patrents.     

Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma

BACKGROUND/AIMS: To investigate the prognostic significances of dendritic cells and lymphocytes infiltration in hepatocellular carcinoma. METHODOLOGY: The clinicopathological and follow-up data of 44 patients with hepatocellular carcinoma, who underwent curative resection of tumor in our hospital from January 1995 to July 1996, were collected. Immunohistochemical staining was employed to detect the S-100 positive dendritic cells in the tumor tissue, and lymphocytes infiltration was evaluated simultaneously. The relationship of the tumor-infiltrating dendritic cells and lymphocytes to the postoperative recurrence-free time and survival rate was analyzed. RESULTS: Either the tumor-infiltrating dendritic cells or the tumor-infiltrating lymphocytes alone had no significant relationship to the postoperative recurrence-free time and survival rate. By taking into consideration both tumor-infiltrating dendritic cells and lymphocytes simultaneously, the patients were classified into two groups. Group A included patients having dendritic cell counts > or = 20 cells/10 high power fields together with positive lymphocytes infiltration (n = 17), and group B consisted of patients having dendritic cell count > or = 20 cells/10 high power fields but with negative lymphocytes infiltration or dendritic cell count < 20 cells/10 high power fields with either positive or negative lymphocytes infiltration (n = 27). There were no significant differences in clinicopathological features between two groups. The recurrence-free time was markedly longer in group A as compared with group B, with a median time of 21.6 months for group A and 4.1 months for group B (P < 0.05). The 1-, 3-, 4-year survival rates were significantly greater in group A than those in group B, being 83.5% vs. 42.2%, 61.8% vs. 28.4% and 48.7% vs. 23.0%, respectively (P < 0.01). CONCLUSIONS: Marked infiltration of dendritic cells together with lymphocytes in tumor tissue was closely related to the improved clinical prognosis in patients with hepatocellular carcinoma, and represented as an independent prognostic factor.